S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Revolutionary Device Redefines Cancer Detection (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Revolutionary Device Redefines Cancer Detection (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Revolutionary Device Redefines Cancer Detection (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Revolutionary Device Redefines Cancer Detection (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: World stocks track Wall Street gains, Japan shares hit record high
China's manufacturing activity contracts for 5th straight month despite policy support
NASDAQ:REPH

Recro Pharma (REPH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$1.47
$2.11
52-Week Range
N/A
Volume
141,800 shs
Average Volume
126,298 shs
Market Capitalization
$117.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

REPH stock logo

About Recro Pharma Stock (NASDAQ:REPH)

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.


REPH Stock News Headlines

Fuji Pharma Co. Ltd.
Here's what Wall Street expects from Recro Pharma's earnings report
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
What Wall Street expects from Recro Pharma's earnings
Mankind Pharma Ltd (MNKI)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Societal CDMO Inc
Is Recro Pharma (REPH) a Worthy Investment?
Recap: Recro Pharma Q4 Earnings
Recro Signs Renewable Energy Agreement With Georgia Power
See More Headlines
Receive REPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/01/2022
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REPH
Employees
185
Year Founded
N/A

Profitability

Net Income
$-11,370,000.00
Pretax Margin
-15.09%

Debt

Sales & Book Value

Annual Sales
$75.36 million
Book Value
$0.90 per share

Miscellaneous

Free Float
48,412,000
Market Cap
$117.93 million
Optionable
Optionable
Beta
1.08
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives















REPH Stock Analysis - Frequently Asked Questions

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) released its quarterly earnings data on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. Recro Pharma had a negative trailing twelve-month return on equity of 56.66% and a negative net margin of 15.15%. During the same quarter in the previous year, the firm posted ($0.48) EPS.

What other stocks do shareholders of Recro Pharma own?
This page (NASDAQ:REPH) was last updated on 3/1/2024 by MarketBeat.com Staff